{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:14:12Z","timestamp":1780402452877,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":4910,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1093\/annonc\/mdl093","type":"journal-article","created":{"date-parts":[[2006,5,3]],"date-time":"2006-05-03T01:30:52Z","timestamp":1146619852000},"page":"1072-1082","source":"Crossref","is-referenced-by-count":48,"title":["Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases"],"prefix":"10.1016","volume":"17","author":[{"given":"M.","family":"Botteman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Barghout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Brandman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1093\/annonc\/mdl093_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/ejso.1998.0593","article-title":"British Association of Surgical Oncology Guidelines. The management of metastatic bone disease in the United Kingdom. The Breast Speciality Group of the British Association of Surgical Oncology","volume":"25","year":"1999","journal-title":"Eur J Surg Oncol"},{"key":"10.1093\/annonc\/mdl093_bb0015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/annonc\/mdi162","article-title":"Bisphosphonate in breast cancer","volume":"16","author":"Coleman","year":"2005","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdl093_bb0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Med Care"},{"issue":"suppl 1","key":"10.1093\/annonc\/mdl093_bb0025","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/8756-3282(91)90066-R","article-title":"An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone","volume":"12","author":"Biermann","year":"1991","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdl093_bb0030","first-page":"24","article-title":"Impact of skeletal complications on total medical care costs in breast cancer patients with bone metastases. Poster Presented at \u2018WHAT IS NEW IN BISPHOSPHONATES? Seventh Workshop on Bisphosphonates\u2014From the Laboratory to the Patient. Davos, Switzerland","author":"Delea","year":"2004","journal-title":"March"},{"key":"10.1093\/annonc\/mdl093_bb0035","first-page":"72","article-title":"The Netherlands","volume":"04","author":"Groot MT, Sleeboom HP, Gerritsen W, Uyl-de Groot CA. Cost of breast cancer, metastatic to the bone, in the Netherlands. Institute for Medical Technology Assessment. Erasmus MC, University Medical Center Rotterdam, Rotterdam","year":"2004","journal-title":"Report"},{"issue":"3","key":"10.1093\/annonc\/mdl093_bb0040","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0302-2838(03)00007-1","article-title":"Costs of prostate cancer, metastatic to the bone","volume":"43","author":"Groot","year":"2003","journal-title":"in the Netherlands. Eur Urol"},{"issue":"5","key":"10.1093\/annonc\/mdl093_bb0045","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1586\/14737167.4.5.565","article-title":"Cost of multiple myeloma and associated skeletal-related events in the Netherlands","volume":"4","author":"Groot","year":"2004","journal-title":"Expert Rev Pharmacoecon Outcome Res"},{"key":"10.1093\/annonc\/mdl093_bb0050","first-page":"1","article-title":"Bone mestastases in breast cancer","author":"Lipton","year":"2004","journal-title":"Business Briefing: US Oncology Review"},{"key":"10.1093\/annonc\/mdl093_bb0055","first-page":"1735","article-title":"Safety of Zoledronic Acid Compared with Pamidronate Disodium in the Treatment of Skeletal Complications in Patients with Advanced Multiple Myeloma or Breast Carcinoma A Randomized, Double-Blind, Multicenter","volume":"98","author":"Rosen","year":"2003","journal-title":"Comparative Trial. Cancer"},{"issue":"suppl 4","key":"10.1093\/annonc\/mdl093_bb0060","first-page":"28","article-title":"Conte and Guarneri. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens","volume":"9","year":"2004","journal-title":"The Oncologist"},{"issue":"7","key":"10.1093\/annonc\/mdl093_bb0065","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s005200100249","article-title":"Schulman KA. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease","volume":"9","author":"DesHarnais Castel","year":"2001","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdl093_bb0070","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00520-004-0628-z","article-title":"Bisphosphonate infusions: patient preference, safety and clinic use","volume":"12","author":"Chern","year":"2004","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdl093_bb0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1191\/026921601671919596","article-title":"Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK","volume":"15","author":"Johnson","year":"2001","journal-title":"Palliat Med"},{"issue":"4","key":"10.1093\/annonc\/mdl093_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8040","article-title":"A systematic review of the role of bisphosphonates in metastatic disease","volume":"8","author":"Ross","year":"2004","journal-title":"Health Technol Assess"},{"key":"10.1093\/annonc\/mdl093_bb0085","author":"De Cock","year":"2005","journal-title":"Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdl093_bb0090","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1185\/030079905X40472","article-title":"Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK","volume":"21","author":"Guest","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"15","key":"10.1093\/annonc\/mdl093_bb0095","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdl093_bb0100","first-page":"1869","article-title":"Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs","volume":"92","author":"Wardley","year":"2005","journal-title":"hospital bisphosphonate administration. Br J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdl093_bb0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdl093_bb0110","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdl093_bb0115","first-page":"3383","article-title":"Efficacy of Pamidronate in breast cancer with bone metastases: A randomized double blind placebo controlled multicenter study","volume":"19","author":"Hultborn","year":"1999","journal-title":"Anticancer Research"},{"issue":"1","key":"10.1093\/annonc\/mdl093_bb0120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.2000.18.1.72","article-title":"Pamidronate in Prevention of Bone Complications in Metastatic Breast Cancer: A Cost-Effectiveness Analysis","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl093_bb0125","doi-asserted-by":"crossref","unstructured":"Pavlakis N, Stockler M. Bisphosphonates for breast cancer. The Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No.: CD003474. DOI: 10.1002\/14651858.CD003474.","DOI":"10.1002\/14651858.CD003474"},{"key":"10.1093\/annonc\/mdl093_bb0130","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl093_bb0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdl093_bb0140","first-page":"1097","article-title":"Bisphosphonates, pain and quality of life in metastatic breast cancer patients: a literature review","volume":"90","author":"Roemer-Becuwe","year":"2003","journal-title":"Bull Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdl093_bb0145","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind","volume":"7","author":"Rosen","year":"2001","journal-title":"comparative trial. Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdl093_bb0150","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","article-title":"MF 4265 Study Group. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel","year":"2004","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdl093_bb0155","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"issue":"7","key":"10.1093\/annonc\/mdl093_bb0160","first-page":"701","article-title":"Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases","volume":"88","author":"Tubiana-Hulin","year":"2001","journal-title":"Bull Cancer"},{"key":"10.1093\/annonc\/mdl093_bb0165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: a randomized study","volume":"246","author":"Kristensen","year":"1999","journal-title":"J Intern Med"},{"key":"10.1093\/annonc\/mdl093_bb0170","article-title":"Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases","author":"Diel","year":"1999","journal-title":"Proc Annu Meet Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl093_bb0175","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.10-1-52","article-title":"Recommendatons for zoledronic acid treatment of patients with bone metastases","volume":"10","author":"Berenson","year":"2005","journal-title":"The Oncologist"},{"key":"10.1093\/annonc\/mdl093_bb0180","first-page":"1133","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised","volume":"90","author":"Body","year":"2004","journal-title":"placebo controlled phase III studies. Br J Cancer"},{"key":"10.1093\/annonc\/mdl093_bb0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s005200050260","article-title":"Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer","volume":"7","author":"Dranitsaris","year":"1999","journal-title":"Support Care Cancer"},{"issue":"21","key":"10.1093\/annonc\/mdl093_bb0190","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl093_bb0195","unstructured":"Major P. Gastrointestinal adverse events can reduce compliance with oral bisphosphonate therapy and result in early study termination. Presented at: What Is New in Bisphosphonates? Seventh Workshop on Bisphosphonates-From the Laboratory to the Patient; March 24-26, 2004; Davos, Switzerland. Poster 58."},{"issue":"S1","key":"10.1093\/annonc\/mdl093_bb0200","first-page":"S49","article-title":"Poor persistency with oral bisphosphonates in cancer patients with bone metastasis","volume":"31","author":"G\u00f6l","year":"2005","journal-title":"Cancer Treatment Reviews"},{"key":"10.1093\/annonc\/mdl093_bb0205","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1008386501738","article-title":"Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease","volume":"10","author":"Coleman","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl093_bb0210","doi-asserted-by":"crossref","unstructured":"Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. The Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD002068. DOI: 10.1002\/14651858.CD002068.","DOI":"10.1002\/14651858.CD002068"},{"key":"10.1093\/annonc\/mdl093_bb0215","unstructured":"British National Formulary (BNF No. 49 (March 2005) www.bnf.org\/bnf\/bnf\/current\/accessed June 6, 2005)."},{"issue":"5","key":"10.1093\/annonc\/mdl093_bb0220","first-page":"437","article-title":"Does NICE have a cost-effectiveness threshold and what other factors influence its decisions?","volume":"13","author":"Devlin","year":"2004","journal-title":"A binary choice analysis. Health Econ"},{"issue":"4","key":"10.1093\/annonc\/mdl093_bb0225","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/027298902400448867","article-title":"Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease","volume":"22","author":"Briggs","year":"2002","journal-title":"Med Decis Making"},{"issue":"5","key":"10.1093\/annonc\/mdl093_bb0230","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1634\/theoncologist.10-5-317","article-title":"Bisphosphonate safety and tolerability","volume":"10","author":"Body","year":"2005","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdl093_bb0235","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1634\/theoncologist.10-5-318","article-title":"In: Response to body letter to the editor regarding, safety of intravenous and oral bisphosphonates and compliance with dosing regimens'","volume":"10","author":"Conte","year":"2005","journal-title":"Oncologist"},{"issue":"5","key":"10.1093\/annonc\/mdl093_bb0240","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1634\/theoncologist.10-5-315","article-title":"In: response to Jackson Letter to the Editor regarding 'Safety of intravenous and oral bisphosphonates and compliance with dosing regimens'","volume":"10","author":"Conte","year":"2005","journal-title":"Oncologist"},{"issue":"5","key":"10.1093\/annonc\/mdl093_bb0245","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1634\/theoncologist.10-5-313","article-title":"Safety and compliance of intravenous and oral dosing regimens","volume":"10","author":"Jackson","year":"2005","journal-title":"Oncologist"},{"issue":"suppl 1","key":"10.1093\/annonc\/mdl093_bb0250","first-page":"S91","article-title":"Assessing the efficacy of ibandronate for the prevention of skeletal-related events (SREs) in metastatic bone disease a methodological comparison","volume":"34","author":"Tripathy","year":"2004","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdl093_bb0255","article-title":"Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone","author":"Body","year":"1999","journal-title":"ASCO Annual Meeting"},{"key":"10.1093\/annonc\/mdl093_bb0260","unstructured":"NHS Reference Costs 2004. 7 March 2005 (revised figures published 14 March 2005) http:\/\/www.dh.gov.uk\/assetRoot\/04\/10\/55\/61\/04105561.xls. (Last accessed June 10, 2005)."},{"key":"10.1093\/annonc\/mdl093_bb0265","series-title":"Unit costs of health & social care 2004","author":"Netten","year":"2004"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341945388X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341945388X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/17\/7\/1072\/564115\/mdl093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T10:08:51Z","timestamp":1624442931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341945388X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S092375341945388X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdl093","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}